$DWTX
Dogwood Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021007163 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.350M $320.0K
YoY Change 321.88% 0.0%
% of Gross Profit
Research & Development $1.707M $30.54K
YoY Change 5489.43% -49.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.057M $382.6K
YoY Change 699.22% 0.67%
Operating Profit -$3.057M -$382.6K
YoY Change 699.22%
Interest Expense $0.00 -$80.00K
YoY Change -100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $1.400K -$84.00K
YoY Change -101.67%
Pretax Income -$3.056M -$466.6K
YoY Change 555.02% 1.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.056M -$466.6K
YoY Change 555.02% 1.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.37 -$60.03K
COMMON SHARES
Basic Shares Outstanding 8.326M
Diluted Shares Outstanding 8.326M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.59M
YoY Change
Cash & Equivalents $24.59M $1.195M
Short-Term Investments
Other Short-Term Assets $3.690M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.27M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $28.27M
Total Long-Term Assets $0.00
Total Assets $28.27M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $614.7K
YoY Change
Accrued Expenses $552.6K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.167M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.167M
Total Long-Term Liabilities $0.00
Total Liabilities $1.167M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$31.00M
YoY Change
Common Stock $833.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.11M
YoY Change
Total Liabilities & Shareholders Equity $28.27M
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.056M -$466.6K
YoY Change 555.02% 1.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.112M -$277.4K
YoY Change 1743.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -97.60K 1.163M
YoY Change -108.4%
NET CHANGE
Cash From Operating Activities -5.112M -277.4K
Cash From Investing Activities
Cash From Financing Activities -97.60K 1.163M
Net Change In Cash -5.210M 885.1K
YoY Change -688.6%
FREE CASH FLOW
Cash From Operating Activities -$5.112M -$277.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
CY2021Q1 dei City Area Code
CityAreaCode
866
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
620-8655
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818844
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8305075
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-39811
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3688977
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1677365
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8330390
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24585560
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29795366
CY2021Q1 dei Trading Symbol
TradingSymbol
VIRI
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8305075
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
833
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
830
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Assets Current
AssetsCurrent
28274537
CY2020Q4 us-gaap Assets Current
AssetsCurrent
31472731
CY2021Q1 us-gaap Assets
Assets
28274537
CY2020Q4 us-gaap Assets
Assets
31472731
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
614659
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
368905
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
552635
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
784104
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
378833
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1167294
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1531842
CY2021Q1 us-gaap Liabilities
Liabilities
1167294
CY2020Q4 us-gaap Liabilities
Liabilities
1531842
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58127548
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57905164
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31021138
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27965105
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
27107243
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28274537
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31472731
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1706957
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30539
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1350476
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
352014
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
3057433
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
382553
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3057433
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-382553
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1400
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-84000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1400
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-84000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3056033
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-466553
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-466553
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8326010
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4832494
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24825
CY2021Q1 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
197562
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
27107243
CY2019Q4 us-gaap Members Equity
MembersEquity
-5017509
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-466553
CY2020Q1 us-gaap Members Equity
MembersEquity
-5484062
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-466553
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10623
CY2020Q1 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
100
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
24825
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2011612
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6404
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
530803
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
73848
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-221352
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
81840
CY2021Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-378833
CY2020Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
29167
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5112202
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-277379
CY2020Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1162500
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
197562
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
295166
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97604
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1162500
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5209806
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
885121
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29795366
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
309384
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24585560
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1194505
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
29214
CY2020Q1 viri Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
35000
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2020Q4 viri Warrants Exercise Price As Percenatge Of Initial Public Offering Price
WarrantsExercisePriceAsPercenatgeOfInitialPublicOfferingPrice
1.25
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-466553
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5112202
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-277379
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31000000.0
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1206366
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1586042
CY2021Q1 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
2178854
CY2020Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
85270
CY2021Q1 viri Prepaid Investigator Meeting Expenses
PrepaidInvestigatorMeetingExpenses
253582
CY2021Q1 viri Prepaid Services
PrepaidServices
50175
CY2020Q4 viri Prepaid Services
PrepaidServices
5729
CY2020Q4 viri Miscellaneous Receivables
MiscellaneousReceivables
324
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3688977
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1677365
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
226930
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
573479
CY2021Q1 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2020Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2021Q1 viri Accrued Contract Research And Manufacturing Costs Current
AccruedContractResearchAndManufacturingCostsCurrent
44188
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
93432
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
22540
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
552635
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
784104
CY2020Q1 us-gaap Notes Payable
NotesPayable
4837500
CY2020Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
73192
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2021Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y8M19D
CY2021Q1 viri Warrants And Rights Intrinsic Value
WarrantsAndRightsIntrinsicValue
0
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2316000

Files In Submission

Name View Source Status
0001558370-21-007163-index-headers.html Edgar Link pending
0001558370-21-007163-index.html Edgar Link pending
0001558370-21-007163.txt Edgar Link pending
0001558370-21-007163-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210331.xsd Edgar Link pending
tmb-20210331x10q.htm Edgar Link pending
tmb-20210331x10q_htm.xml Edgar Link completed
tmb-20210331xex31d1.htm Edgar Link pending
tmb-20210331xex31d2.htm Edgar Link pending
tmb-20210331xex32d1.htm Edgar Link pending
tmb-20210331xex32d2.htm Edgar Link pending
tmb-20210331_cal.xml Edgar Link unprocessable
tmb-20210331_def.xml Edgar Link unprocessable
tmb-20210331_lab.xml Edgar Link unprocessable
tmb-20210331_pre.xml Edgar Link unprocessable